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Abstract
The enantioselective synthesis of α-disubstituted N-heterocyclic carbonyl compounds has been 
accomplished using palladium-catalyzed allylic alkylation. These catalytic conditions enable 
access to various heterocycles, such as morpholinone, thiomorpholinone, oxazolidin-4-one, 1,2-
oxazepan-3-one, 1,3-oxazinan-4-one and structurally related lactams, all bearing fully substituted 
α-positions. Broad functional group tolerance was explored at the α-position in the morpholinone 
series. We demonstrate the utility of this method by performing various transformations on our 
useful products to readily access a number of enantioenriched compounds.
Graphical Abstract
N,O-heterocycles such as morpholine, oxazolidine, and isoxazolidine are important 
pharmacophores in medicinal chemistry (figure 1).1–11 Notable morpholine-containing 
pharmaceuticals include edivoxetine2, an antidepressant and a treatment for ADHD; 
linezolid5, a synthetic antibiotic; and gefitinib4, an EGFR inhibitor used to treat certain 
breast, lung and other cancers. 5-Membered isoxazolidinone is the core structure of 
cycloserine8, an antibiotic for the treatment of tuberculosis. Quinocarcin7, possessing an 
oxazolidine ring in the 3,8-diazabicyclo[3.2.1]octane framework, has shown remarkable 
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antiproliferative activity against lymphocytic leukemia. An antibiotic, FR-669799, isolated 
from Streptomyces sandaensis No. 6897, contains a 1,2-oxazinane moiety.
In addition to a wide variety of biological activity, N,O-heterocycles shown in Figure 2 are 
commonly used as synthetic intermediates, which provide various hydroxy acid moieties 
after acetal removal or N-O bond cleavage. Oxazolidin-4-ones have been reported as good 
platforms to α-hydroxyacids.12 For example, Ye et al.12a reported that the formal [3+2] 
cycloaddition between ketenes and oxaziridines could be applied in an enantioselective 
fashion to synthesize oxazolidin-4-one derivatives, which could be converted into the 
corresponding α-hydroxy acids. 1,2-Oxazinan-3-ones have proved to be excellent precursors 
to γ-hydroxy acid and γ-butyrolactone derivatives.13
Our group has a sustained interest in the enantioselective synthesis of α-quaternary carbonyl 
compounds,14 – 16 which offers a novel solution for these challenging chiral centers in 
natural product synthesis. Influenced by our results, the Lupton group17a and the Shao 
group17b simultaneously reported that carbazolones are suitable substrates under our allylic 
alkylation conditions and applied the resulting chiral building blocks to total syntheses of 
indole alkaloids. Significant work in our laboratory has identified conditions for the 
enantioselective allylic alkylation to provide α-quaternary lactams in exceptional yields and 
enantioselectivities.14b As part of that endeavor, we reported that 2-allyl-2-
methylmorpholin-3-one 2a was obtained in a similar manner in high yield (91% yield) and 
outstanding enantioselectivity (99% ee). We sought to extend the substrate scope to 
morpholine derivatives and postulated that a broadly expanded array of chiral N,O-
heterocyles might be readily accessible using our palladium-catalyzed allylic alkylation. 
Herein, we describe enantioselective allylic alkylation of heterocycles, including 
morpholin-3-one, thiomorpholine-3-one, oxazolidin-4-one, 1,2-oxazepan-3-one and 1,3-
oxazinan-4-one.18 Furthermore, the enantioenriched products obtained were successfully 
converted into useful asymmetric building blocks containing quaternary and tetrasubstituted 
tertiary chiral centers.
We prepared a collection of racemic morpholinone substrates 1a-e19 and performed 
palladium-catalyzed decarboxylative allylic alkylation with Pd2(dba)3 (5 mol %) and (S)-
(CF3)3-t-BuPHOX ligand20 (12.5 mol %, PHOX = phosphinooxazo-line) in a 0.033 M 
solution of toluene (Figure 3). Simple α-benzyl substitution performed well in this 
chemistry; the desired 2-benzyl α-tetrasubstituted morpholinone 2b was obtained in 95% 
yield and 99% ee. Gratifyingly, other functionalized substrates (benzyl ether, methyl ester, 
nitrile) are well tolerated, affording α-functionalized morpholinones 2c, 2d and 2e in 
uniformly excellent enantioenrichment (99% ee), although the yield of 2d was moderate 
(60%). Having demonstrated a broad functional group tolerance within the side chain, we 
explored other ring sizes and frameworks. Replacement of oxygen with sulfur gave 
thiomorpholinone 2f in good yield, but slightly decreased enantioselectivity (79% yield, 
86% ee). Like morpholinone, benzomorpholinone is also a good substrate class, delivering 
allylated product 2g in 76% yield and 95% ee. Additionally, α-tetrasubstituted oxazolidin-4-
one 2h is produced in 82% yield and 96% ee with higher temperature applied (60 °C).21 
Benzyloxazolinone 2i is also produced in good yield and enantioselectivity.
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With excellent results on α,α-dialkyl 2-oxa- and thia-linked lactams in hand, we started to 
investigate allylic alkylation using cyclic hydroxamic acid derivatives to obtain a-quaternary 
N,O-heterocycles (Table 1). Isoxazolidin-3-one 3a (R = Bz), 3b (R = Boc) and 3c (R = 
CO2Ph) produced the desired alkylated compounds 4a-c in excellent yields (95–98%), but 
with modest enantioselectivities (72–73% ee) (entries 1–3). Benzoyl protected 1,2-
oxazinan-3-one 3d underwent an unexpected side reaction, and produced only small 
amounts of 4d (entry 4).24 Despite of the low yield, the enantioselectivity of 4d is still 
satisfactory (88% ee), which encouraged us to identify an effective N-protecting group to 
circumvent the undesired reaction. A bulky pivaloyl group somehow suppresses the side 
reaction, but decreases the enantioselectivity (entry 5). An electron-rich N-benzylated 3f was 
a poor substrate for decarboxylative alkylation (entry 6).25 Finally, we discovered that 
carbamates 3g-i produced the desired products in good yields (67–89%) and acceptable 
enantioselectivities (84–87% ee) (entries 7–9), with little or none of the undesired side 
reactivity observed. We were delighted to find that 7-membered 3j is an excellent substrate 
in this class, furnishing 4j in a good yield and excellent enantioselectivity (entry 10, 81% 
yield, 93% ee).
As shown in Scheme 1, we have also demonstrated allylic alkylation with 1,3-oxazinan-4-
one 5 as an alternative β-hydroxy acid synthon of 3a. To our delight, 5 was successfully 
converted into 6 in 90% yield and 94% ee.
We anticipate that our newly developed heterocycles could play important roles in medicinal 
agent discovery and also serve as useful chiral building blocks. To demonstrate the value and 
versatility of this new class of α-tetrasubstituted heterocycles, we implemented a number of 
product transformations (Scheme 2). For example, removal of the benzoyl group followed 
by reduction using LiAlH4 can readily convert morpholinone 2c into N-H morpholine 7. 
Acid treatment of 2h in methanol provided α-tertiary-hydroxy ester 8 in 71% yield without 
erosion of enantiopurity.26 a-Quaternary δ-lactone 9 was synthesized from 4j in a good yield 
by zinc mediated reduction of the N-O bond followed by acid catalyzed cyclization.
In conclusion, we have developed a variety of new classes of substrates for catalytic 
enantioselective allylic alkylation to generally form α,α-disubstituted 2-keto heterocycles, 
such as morpholinones, oxazolidinones, cyclic hydroxamic acid derivatives, and 1,3-
oxazinanones. The asymmetric products formed in this communication are envisioned to be 
valuable pharmacophores in medicinal chemistry and their transformations afford a variety 
of important structures such as chiral hydroxy acid derivatives. Studies utilizing this method 
toward the synthesis of complex natural products and other bioactive small molecules are 
ongoing in our laboratory.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
ACKNOWLEDGMENT
The authors wish to thank NIH-NIGMS (R01GM080269 to B.M.S. and R01GM075962 to K.N.H), Amgen, the 
Gordon and Betty Moore Foundation, the Caltech Center for Catalysis and Chemical Synthesis, and Caltech for 
Numajiri et al. Page 3
Org Lett. Author manuscript; available in PMC 2019 March 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
financial support. Y.N. thanks Toray Industries Inc. for a postdoctoral fellowship. G.J.-O. and K.N.H. used the 
Extreme Science and Engineering Discovery Environment (XSEDE) supported by grant (OCI-1053575) along with 
the UCLA Institute of Digital Research and Education (IDRE). The authors are grateful to Dr. Rina Dukor 
(BioTools) for helpful discussions. The authors thank Scott Virgil (Caltech) for instrumentation assistance and Dr. 
Douglas C. Behenna (Caltech) for initial experimental results.
REFERENCES
(1). For reviews, see:Wijtmans R; Vink MKS; Schoemaker HE; van Delft FL; Blaauw RH; Rutjes 
FPJT Synthesis 2004, 641.Aroney M; Le Fevre RJW J. Chem. Soc. 1958, 3002.
(2). (a)Dube S; Dellva MA; Jones M; Kielbasa W; Padich R; Saha A; Rao PJ Psychiatr. Res 2010, 44, 
356.(b)Pangallo B; Dellva MA; D’Souza DN; Essink B; Russell J; Goldberger CJ Psychiatr. Res 
2011, 45, 748.
(3). Hale JJ; Mills SG; MacCoss M; Finke PE; Cascieri MA; Sadowski S; Ber E; Chicchi GG; Kurtz 
M; Metzger J; Eiermann G; Tsou NN; Tattersall FD; Rupniak NMJ; Williams AR; Rycroft W; 
Hargreaves R; MacIntyre DE J. Med. Chem 1998, 41, 4607. [PubMed: 9804700] 
(4). (a)Morie T; Kato S; Harada H; Yoshida N; Matsumoto J Chem. Pharm. Bull 1994, 42, 877. 
[PubMed: 8020122] (b)Mine Y; Yoshikawa T; Oku S; Nagai R; Yoshida N; Hosoki KJ 
Pharmacol. Exp. Ther 1997, 283, 1000.
(5). (a)Barker AJ; Gibson KH; Grundy W; Godfrey AA; Barlow JJ; Healy MP; Woodburn JR; Ashton 
SE; Curry BJ; Scarlett L; Henthorn L; Richards L Bioorg. Med. Chem. Lett 2001, 11, 1911. 
[PubMed: 11459659] (b)Sirotnak FM; Zakowski MF; Miller VA; Scher HI; Kris MG Clin. 
Cancer Res. 2000, 6, 4885. [PubMed: 11156248] 
(6). Brickner SJ; Hutchinson DK; Barbachyn MR; Manninen PR; Ulanowicz DA; Garmon SA; Grega 
KC; Hendges SK; Toops DS; Ford CW; Zurenko GE J. Med. Chem 1996, 39, 673. [PubMed: 
8576909] 
(7). Cang S; Ohta S; Chiba H; Johdo O; Nomura H; Nagamatsu Y; Yoshimoto AJ Antibiot. 2001, 54, 
304.
(8). (a)Tomita F; Takahashi K; Shimizu KJ. Antibiot 1983, 36, 463. [PubMed: 6860429] (b)Takahashi 
K; Tomita F J. Antibiot 1983, 36, 468. [PubMed: 6874563] (c)Tomita F; Takahashi K; Tamaoki T 
J. Antibiot 1984, 37, 1268. [PubMed: 6094411] 
(9). (a)Epstein IG; Nair KG; Boyd LJ Antibiot. Med. Clin. Ther 1955, 1, 80.(b)Welch H; Putnam LE; 
Randall WA Antibiot. Med. Clin. Ther 1955, 1, 72.(c)Hidy PH; Hodge EB; Young VV; Harned 
RL; Brewer GA; Phillips WF; Runge WF; Stavely HE; Pohland A; Boaz H; Sullivan HR J. Am. 
Chem. Soc 1955, 77, 2345.(d)Ressler KJ; Rothbaum BO; Tannenbaum L; Anderson P; Graap K; 
Zimand E; Hodges L; Davis M Arch. Gen. Psychiatry 2004, 61, 1136. [PubMed: 15520361] 
(10). (a)Terano H; Takase S; Hosoda J; Kohsaka MJ Antibiot. 1989, 42, 145.(b)Rajski SR; Rollins SB; 
Williams RM J. Am. Chem. Soc 1998, 120, 2192.
(11). (a)Kuehne ME; Konopka EA J. Med. Chem 1962, 5, 257.(b)Chylinska JB; Urbanski T; 
Mordarski M. J. Med. Chem 1963, 6, 484. [PubMed: 14173566] 
(12). (a)Shao P-L; Chen X-Y; Ye S Angew. Chem., Int. Ed 2010, 49, 8412.(b)Ooi T; Fukumoto K; 
Maruoka K Angew. Chem., Int. Ed 2006, 45, 3839.(c)Cardillo G; Hashem MA; Tomasini C J. 
Chem. Soc., Perkin Trans. 1 1990, 1487.(d)Roush WR; Essenfeld AP; Warmus JS; Brown BB 
Tetrahedron Lett. 1989, 30, 7305.
(13). (a)Ranganathan S; Ranganathan D; Mehrotra AK J. Am. Chem. Soc 1974, 96, 5261.(b)Clarke 
PA; Cridland AP; Rolla GA; Iqbal M; Bainbridge NP; Whitwood AC; Wilson CJ. Org. Chem 
2009, 74, 7812. [PubMed: 19813768] 
(14). (a)Behenna DC; Mohr JT; Sherden NH; Marinescu SC; Harned AM; Tani K; Seto M; Ma S; 
Novak Z; Krout MR; McFadden RM; Roizen JL; Enquist JA, Jr.; White DE; Levine SR; Petrova 
KV; Iwashita A; Virgil SC; Stoltz BM Chem. Eur. J 2011, 17, 14199. [PubMed: 22083969] 
(b)Behenna DC; Liu Y; Yurino T; Kim J; White DE; Virgil SC; Stoltz BM Nature Chem. 2012, 4, 
130.(c)Bennett NB; Duquette DC; Kim J; Liu W-B; Marziale AN; Behenna DC; Virgil SC; Stoltz 
BM Chem. Eur. J 2013, 19, 4414. [PubMed: 23447555] (d)Reeves CM; Eidamshaus C; Kim J; 
Stoltz BM Angew. Chem., Int. Ed 2013, 52, 6718.
Numajiri et al. Page 4
Org Lett. Author manuscript; available in PMC 2019 March 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
(15). (a)Liu W-B; Reeves CM; Virgil SC; Stoltz BM J. Am. Chem. Soc 2013, 135, 10626. [PubMed: 
23829704] (b)Liu W-B; Reeves CM; Stoltz BM J. Am. Chem. Soc 2013, 135, 17298. [PubMed: 
24160327] 
(16). Ma S; Han X; Krishnan S; Virgil SC; Stoltz BM Angew. Chem., Int. Ed 2009, 48, 8037.
(17). (a)Gartshore CJ; Lupton DW Angew. Chem., Int. Ed 2013, 52, 4113.(b)Li Z; Zhang S; Wu S; 
Shen X; Zou L; Wang F; Li X; Peng F; Zhang H; Shao Z Angew. Chem., Int. Ed 2013, 52, 4117.
(18). For examples of α,α-dialkylated ketopiperazine synthesis, see:Korch KM; Eidamshaus C; 
Behenna DC; Nam S; Horne D; Stoltz BM Angew. Chem. Int. Ed 2015, 54, 179.
(19). For preparation of substrates, see ref 14b and supporting information.
(20). McDougal NT; Streuff J; Mukherjee H; Virgil SC; Stoltz BM Tetrahedron Lett. 2010, 51, 5550. 
[PubMed: 21076623] 
(21). The substrate 1h can be readily prepared from commercially available lactamide in three steps.19
(22). Stephens PJ; Devlin FJ; Cheeseman JR VCD Spectroscopy for Organic Chemists; CRC Press: 
Boca Raton, FL, 2012.
(23). Seto M; Roizen JL; Stoltz BM Angew. Chem., Int. Ed 2008, 47, 6873.
(24). We isolated 10 presumably due to retro [4+2] cycloaddition followed by palladium-catalyzed 
alkylation.
(25). We also observed that electron-rich N-alkyl protection of amides decreased the reactivity under 
our conditions, see ref 14b.
(26). For an alternative preparation of a-tertiary-hydroxy carbonyl compounds , see ref 23.
Numajiri et al. Page 5
Org Lett. Author manuscript; available in PMC 2019 March 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Representative N,O-heterocyclic-containing pharmaceuticals and natural products
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Figure 2. 
α-Tertiary and quaternary N,O-heterocycles
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Figure 3. Substrate Scope of α-Tertiary Heterocyclesa
aReaction performed with 0.1 mmol of 1, 5 mol % of Pd2(dba)3, 12.5 mol % of (S)-(CF3)3-
t-BuPHOX at 0.033 M in toluene at 50 °C bDetermined by chiral SFC analysis. cReactions 
were performed on 1g, 1h and 1i at 60 °C. dThe ee of 2g was determined by chiral SFC 
analysis after Bz removal (see supporting information). ePd2(pmdba)3 (pmdba = bis(4-
methoxybenzylidene)acetone) was used instead of Pd2(dba)3. fAbsolute configuration was 
assigned by vibrational circular dichroism (VCD) spectroscopy22 supported by theoretical 
calculations (see supporting information). gAbsolute stereochemistry assigned by conversion 
into (–)-methyl 2-hydroxy-2-methylpent-4-enoate.23
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Scheme 1. 
Synthesis of 1,3-oxazinan-4-one 6
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Scheme 2. 
Derivatization of Allylic Alkylation Products
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Table 1.
Substrate Scope of α-Quaternary Cyclic Hydroxamic Acid Derivativesa
entry substrate R yield (%)b ee (%)c
1 Bz (3a→4a)d 98 73
2 Boc (3b→4b) 95 72
3 PhO(CO) (3c→4c) 95 73
4 Bz (3d→4d) 29 88
5 Piv (3e→4e) 48 73
6 Bn (3f→4f) trace ND
7 Boc (3g→4g) 67 85
8 Cbz (3h→4h) 89 84
9 PhO(CO) (3i→4i) 70 87
10 81 93
a
Reaction performed under the conditions of Figure 3 at 60 °C.
bAll reported yields are for isolated products.
c
Enantiomeric excesses were determined by chiral SFC analysis.
dAbsolute configuration was assigned by VCD spectroscopy22 supported by theoretical calculations (see supporting information).
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